Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932472 | 0.82 | TDP1 (0.42) | TDP1GAAKDM4EALDH1A1GLA | |
| SCHEMBL794166 | 0.81 | BACE1 (0.42) | KDM4EALDH1A1GLAMAPTBACE1 | |
| SCHEMBL10286265 | 0.80 | TDP1 (0.40) | TDP1GAAKDM4EALDH1A1GLA | |
| SCHEMBL22975175 | 0.80 | TDP1 (0.47) | TDP1GAAKDM4EMEN1KMT2A | |
| SCHEMBL20303890 | 0.80 | BACE1 (0.35) | GAABACE1HCRTR2 | |
| SCHEMBL9327452 | 0.78 | TDP1 (0.49) | TDP1GAAKDM4EMAPTMEN1 | |
| SCHEMBL8443417 | 0.78 | CA1 (0.38) | KMT2ABACE1 | |
| SCHEMBL19126937 | 0.78 | EPHX2 (0.39) | KDM4EALDH1A1GLAMAPTBACE1 | |
| SCHEMBL8446546 | 0.77 | BACE1 (0.36) | TDP1GAAMEN1KMT2ABACE1 | |
| SCHEMBL26924955 | 0.77 | BACE1 (0.36) | TDP1GAAMEN1KMT2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108135168-B | CCR2 modulators | 凯莫森特里克斯股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20130296317-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130296317-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-8293762-B2 | Isoquinolinopyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-23 | — | — | US | disclosed |
| WO-2012058193-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2380890-A1 | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-20100056556-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-2120933-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008104475-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-09-04 | — | — | WO | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296317-A1 | LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, PARK7, AKT1 | TDP1 1819/4885GAA 239/4885KDM4E 3972/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | TDP1 4090/4885GAA 4766/4885KDM4E 4548/4885 |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | TDP1 4540/4885GAA 4312/4885KDM4E 2794/4885 |
| US-20100056556-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | TDP1 567/4885GAA 3492/4885KDM4E 513/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | TDP1 3282/4885GAA 4729/4885KDM4E 4739/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | TDP1 4610/4885GAA 4424/4885KDM4E 4745/4885 |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | TDP1 840/4885GAA 3382/4885KDM4E 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.